- (2014): Prescrire Int 23(151), 180
Adverse reactions attributed to entire drug class 'Antibiotic; anthracycline'
Please login to view adverse reactions.
- (2024): Ran T+, PLoS One 19(5), e0303208 [REVIEW]
Cardiac disorder / cardiac dysfunction
- (2024): Stafford LK+, Pharmacogenomics J 24(4), 21
(pharmacogenomics) - (2021): Yu H+, Front Pharmacol Mar (e-Collection) 46%
- (2021): Guha A+, ESC Heart Fail May, Online ahead of print
- (2014): Momomura S, Seishin Shinkeigaku Zasshi (Japanese) 116(2), 123
- (2025): Mohammed S+, bioRxiv Jan, Online ahead of print
- (2025): Vaitiekus D+, Int J Mol Sci 26(9), 4051 ('unlikely that there is a single driver gene in ABCC [Anthracycline-Based Chemotherapy Cardiotoxicity] pathogenesis') (pharmacogenomics)
- (2024): Orimolade OA+, West Afr J Med 41(12), 1174-118157% (with underlying comorbidities in some cases)
- (2020): Rivas-Ruiz R+, Gac Med Mex 156(3), 217-223 (dose-related)
- (2017): Bansal N+, Expert Opin Drug Metab Toxicol 13(8), 817 [REVIEW]
- (2016): Armenian SH, Ann Nutr Metab 68 Suppl 3, 10
- (2016): Chung WB+, Korean J Intern Med 31(4), 625 [REVIEW]
- (2016): Hamirani Y+, Med Oncol 33(7), 82
- (2015): Tan TC+, Compr Physiol 5(3), 1517 [REVIEW]
- (2014): Truong J+, Can J Cardiol 30(8), 869 [REVIEW]
Ventricular dysfunction (left ventricular dysfunction / right ventricular dysfunction)
- (2025): Shugg T+, J Cardiovasc Pharmacol Ther Jan-Dec (e-Collection)
- (2023): Theetha Kariyanna P+, Front Cardiovasc Med Aug (e-Collection) [REVIEW]
- (2022): Chen W+, Medicine (Baltimore) 101(42), e31084
- (2010): Perez-Fidalgo JA+, Breast Cancer Res Treat 120 (1), 245
- (2020): Gadisa DA+, J Oncol Feb (e-Collection) 21% (grade 3)
Neutropenia (neutrophils decreased)
- (2020): Gadisa DA+, J Oncol Feb (e-Collection) 16% (grade 3)
- (2020): Gadisa DA+, J Oncol Feb (e-Collection) 93%
